Lecanemab-LEQEMBI domestic marketing progress and clinical use

Lecanemab (lecanemab)-LEQEMBI is a new antibody drug targeting β-amyloid protein. It is mainly used for the treatment of patients with early Alzheimer's disease (AD). The drug selectively targets soluble and oligomeric β-amyloid in the brain, thereby slowing down its deposition and neurotoxic effects, providing the possibility to improve cognitive function. The domestic demand for treatment of patients with early Alzheimer's disease is gradually increasing, which has attracted much attention for the domestic launch and clinical application of LEQEMBI.

Currently, lencanezumab has been approved for marketing in the country, but it has not yet been included in the medical insurance system. If patients want to use this drug, they need to obtain it through specific hospitals and formal channels. Since the drug is an injectable preparation, it is usually evaluated and used by a neurologist or cognitive impairment specialist to ensure that the patient meets the indications for early AD treatment and to conduct necessary clinical monitoring during use.

In clinical practice, LEQEMBI is mainly used in patients with early-stage Alzheimer's disease, with the goal of slowing down cognitive and functional decline. Multiple clinical studies have shown that the drug can reduce the β- amyloid load in the brain within 6 to 12 months, and show a certain improvement in cognitive scores. Regular brain imaging examinations and cognitive function assessments are required during treatment to ensure efficacy and safety.

In terms of usage precautions, the domestic clinical application of lencanezumab requires attention to potential risks such as infusion-related reactions, cerebral microbleeds, and cerebral edema. Patients should comprehensively assess their health status, including blood pressure, cerebrovascular history and MRI examination results before receiving treatment. During the medication process, doctors will adjust the treatment plan based on the patient's response and imaging monitoring results to ensure safety and clinical benefits.

Keyword tags: Lencanezumab, Alzheimer's disease, β-Amyloid, domestically marketed, cognitive improvement

Reference materials:https://en.wikipedia.org/wiki/Lecanemab